NCT05845268View on ClinicalTrials.gov

Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

November 1, 2024

Study Completion Date

December 1, 2025

Conditions
Locally Advanced Rectal Cancer
Interventions
COMBINATION_PRODUCT

Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor)

Tislelizumab was added to long-course chemoradiotherapy (CRT) in LARC patients, CRT + concurrent tislelizumab was used in the Experimental arm, and CRT was used in the Active Comparator arm.

COMBINATION_PRODUCT

Long-course chemoradiation, without Tislelizumab (PD-1 inhibitor)

Tislelizumab was added to long-course chemoradiotherapy (CRT) in LARC patients, CRT + concurrent tislelizumab was used in the Experimental arm, and CRT was used in the Active Comparator arm.

Trial Locations (1)

100050

RECRUITING

Beijing Friendship Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Friendship Hospital

OTHER